Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration

Annals of Neurology

Volumn 53, Issue 2, 2003, Pages 174-180

  Kapoor, Raju ^a,b   Davies, Meirion ^a   Blaker, Paul A ^a   Hall, Susan M ^a   Smith, Kenneth J ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c Guy's Campus ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL; CALCIUM ION; FLECAINIDE; LIDOCAINE; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NITRIC OXIDE DONOR; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL ROOT; GUILLAIN BARRE SYNDROME; INFLAMMATION; MALE; MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; MYELINATED NERVE; NERVE FIBER DEGENERATION; NERVE POTENTIAL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM CALCIUM EXCHANGE; VENTRAL ROOT;

ANESTHETICS, LOCAL; ANIMALS; AXONS; BEPRIDIL; CALCIUM; CALCIUM CHANNEL BLOCKERS; ELECTROPHYSIOLOGY; FLECAINIDE; LIDOCAINE; MALE; NERVE DEGENERATION; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM; SODIUM CHANNEL BLOCKERS; SODIUM-CALCIUM EXCHANGER; SPINAL NERVE ROOTS;

EID: 0037309442     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10443     Document Type: Article

References (40)

1. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1993;117:49-58.
2. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-1592.
3. Losseff NA, Wang L, Lai M, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119:2009-2019.
4. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469-1477.
5. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51:234-238.
6. Evangelou N, Esiri MM, Smith S, et al. Quantitative pathological evidence of axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391-395.
7. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399.
8. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
9. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000;157:267-276.
10. Bo L, Dawson TM, Wesselingh S, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis. Ann Neurol 1994;36:778-786.
11. Brosnan CF, Battistini L, Raine CS, et al. Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 1994;16:152-161.
12. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9:69-92.
13. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001;49:470-476.
14. Brown GC, Bolanos JP, Heales SJ, Clark JB. Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration. Neurosci Lett 1995;193:201-204.
15. Bolanos JP, Almeida A, Stewart V, et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997;68:2227-2240.
16. 2+ influx during anoxia in mammalian central nervous system white matter. Ann Neurol 1991;30:375-380.
17. 2+-mediated injury in myelinated CNS axons. Brain Res 1994;644:197-204.
18. Lehning EJ, Doshi R, Isaksson N, et al. Mechanisms of injury-induced calcium entry into peripheral nerve myelinated axons: role of reverse sodium-calcium exchange. J Neurochem 1996; 66:493-500.
19. 2+ exchanger. J Neurosci 1992;12:430-439.
20. Stys PK. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cerebral Blood Flow Metabol 1998;18:2-25.
21. Stys PK, Ransom BR, Waxman SG. Tertiary and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J Neurophysiol 1992;67:236-240.
22. Kapoor R, Blaker PA, Hall SM, et al. Protection of axons from degeneration resulting from exposure to nitric oxide. Rev Neurol (Paris) 2000(suppl 3);156:3S67.
23. Shibuki K, Okada D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature 1991;349:326-328.
24. Malinsky T, Bailey F, Zhang ZG, Chopp M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 1993;13:355-358.
25. Hooper DC, Ohnishi ST, Kean R, et al. Local nitric oxide production in' viral and autoimmune diseases of the central nervous system. Proc Natl Acad Sci USA 1995;92:5312-5316.
26. Garthwaite G, Goodwin DA, Batchelor AM, et al. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience 2002;109:145-155.
27. Kleyman TR, Cragoe EJ Jr. Amiloride and its analogs as tools in the study of ion transport. J Membr Biol 1988;105:1-21.
28. Trapp BD, Ransohoff RM, Fisher E, et al. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999;5:48-57.
29. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
30. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-1504.
31. European Study Group on Interferon Beta-1b in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomized trial of interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491-1497.
32. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
33. Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117:759-765.
34. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793.
35. + mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001;159:1701-1710.
36. Bechtold DA, Kapoor R, Smith KJ. Axonal protection mediated by flecainide therapy in experimental inflammatory demyelinating disease. J Neurol 2002;249:(suppl 1):1/204.
37. Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. NeuroReport 2002;13:1909-1912.
38. Schnell L, Fearn S, Klassen H, et al. Acute inflammatory responses to mechanical lesions in the CNS: differences between the brain and spinal cord. Eur J Neurosci 1999;11:3648-3658.
39. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996;27:1739-1743.
40. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999; 9:119-131.